Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > Boehringer Ingelheim & Enleofen Ink $1 Billion+Fibrosis Deal

<< Previous

Bullboard Posts

Next >>

Comment by GunnerGon Jan 10, 2020 10:33am

69 Views

Post# 30538520

RE:Boehringer Ingelheim & Enleofen Ink $1 Billion+Fibrosis Deal

This is the second or turd NR posted by pumpers that a major pharm has spent $1 Billion+ on a Fibrosis Deal. Not sure how you think this is a positive for this company.

Its like picking teams at grade school and LMNL is that last kid to be picked, LOL. You have to wonder why the others are getting bought out and PLI / LMNL can't get it done. Pierre tried for years, the "new management" has been trying for a year; and nothing.

4050 seems to be stalled, could be a reason for that and the majors know it.